ENEdoardo Rosario De Natale

Edoardo Rosario De Natale

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Edoardo Rosario De Natale has a total of 39 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    In Vivo Mapping of Catecholaminergic Loss and Iron Deposition in Huntington's Disease

    by Edoardo R. de Natale, Heather Wilson, Efstratios Karavasilis, Athanasia Liozidou, Chrisoula Kartanou, Georgios Velonakis, Jens Kuhle, Ioannis Zalonis, Georgia Karadima, Leonidas Stefanis, et al.

    Background: The pathophysiology of Huntington's disease (HD) remains obscure. Magnetic resonance imaging (MRI) can reveal in vivo molecular changes related to disease pathology. Objectives: To investigate catecholaminergic neuronal integrity and subcortical brain iron accumulation in HD employing neuromelanin‐sensitive MRI, and quantitative susceptibility mapping (QSM‐MRI). Methods: Twenty‐five HD gene expansion carriers (HDGECs; 11 premanifest, mean predicted phenoconversion time 21.25 ± 8.28 years) and 25 healthy controls (HC) underwent clinical investigation, measurement of plasma neurofilament light chain (NfL) levels, neuromelanin‐sensitive, and QSM‐MRI on a 3 T scanner. For neuromelanin analysis, the substantia nigra (SN) and locus coeruleus (LC) areas and contrast‐to‐noise ratio (CNR) were computed. Regions of interest from the MuSus100 atlas were segmented for QSM‐MRI analysis, and susceptibility values extracted using the whole brain mask as reference. Results: Manifest HDGECs showed, on neuromelanin‐sensitive MRI analysis, reduced LC and SN areas, and LC CNR compared with HC ( P < 0.001). QSM analysis demonstrated increased susceptibility values in caudate, putamen, external and internal pallidum, and the subthalamic nucleus of manifest HGDECs ( P < 0.001). Higher susceptibility values in these regions correlated with clinical markers of disease burden, higher plasma NfL, and poorer neuropsychological outcomes in multiple domains ( P < 0.05). Smaller LC area correlated with higher plasma NfL ( P = 0.029). Higher susceptibility values in the caudate and putamen correlated with lower SN CNR ( P < 0.05). Conclusions: Our findings confirm widespread iron subcortical accumulation in HD, reveal significant noradrenergic neuronal loss, and describe dopaminergic alteration which may reflect ongoing pathology along the nigrostriatal pathway. © 2026 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

  • Open Access

    Loss of serotonergic function in carriers of PRKN mutations: a [11C]DASB PET study

    by Edoardo Rosario de Natale, Heather Wilson, Joji P Verghese, Eoin Mulroy, Savvas Antoniadis, Alana Terry, Francesco Cavallieri, Micol Avenali, Pasquale Nigro, Varvara Valotassiou, et al.

    Purpose: We investigated serotonergic and dopaminergic terminal integrity role in PRKN- associated Parkinsonism (PRKN-PD) using [¹¹C]DASB Positron Emission Tomography (PET) and [¹²³I]FP-CIT Single Photon Emission Computerised Tomography (SPECT). Methods: Fourteen PRKN-PD patients (mean age 49.70 ± 10.83, disease duration 10.95 ± 7.59 years, H&Y 2.0 ± 0.68), and twelve iPD patients (mean age 65.40 ± 7.48 years, disease duration 5.05 ± 4.50 years, H&Y 2.0 ± 0.93) underwent clinical assessments, 3-Tesla MRI, [ 11 C]DASB PET-CT, and [ 123 I]FP-CIT SPECT, and compared with previously acquired healthy control (HCs) data. [ 11 C]DASB distribution volume ratio (DVR) parametric images were generated and DVR-1 values, equivalent to BP ND , sampled from a priori selected regions-of-interest (ROIs) with the posterior cerebellum as reference. [ 123 I]FP-CIT images underwent reconstruction and normalization to standard space, and striatal Specific Binding Ratio (SBR) calculated from the eight hottest consecutive slices. Results: PRKN-PD patients showed 20.8% to 45.2% [ 11 C]DASB BP ND loss across several cortical and subcortical ROIs compared to HCs ( p ≤ 0.01). After adjusting for age and disease duration, no differences in [ 11 C]DASB BP ND were observed between PRKN-PD and iPD. In PRKN-PD, higher [ 11 C]DASB BP ND in the raphe, brainstem, ventral striatum, and amygdala, correlated with higher scores on the Non-Motor Symptoms Scale ( p < 0.05). Higher [ 11 C]DASB BP ND in the caudate and putamen correlated with higher scores on the Beck Depression Inventory II scale ( p < 0.05). No correlation was detected between [ 11 C]DASB BP ND and [ 123 I]FP-CIT SBR in the caudate and putamen. Conclusions: PRKN-PD is characterized by widespread serotonergic dysfunction, which is independent of dopaminergic degeneration and linked to key non-motor symptoms, particularly depression. These findings provide novel insights into the pathophysiology of PRKN-PD.

  • Open Access

    Mitochondrial Complex 1, Sigma 1, and Synaptic Vesicle 2A in Early Drug‐Naive Parkinson's Disease

    by Heather Wilson, Gennaro Pagano, Edoardo Rosario De Natale, Ayla Mansur, Silvia Paola Caminiti, Sotirios Polychronis Msc, Lefkos T. Middleton, Geraint Price, Karl F. Schmidt, Roger Gunn, et al.

    Background Dysfunction of mitochondrial energy generation may contribute to neurodegeneration, leading to synaptic loss in Parkinson's disease (PD). The objective of this study was to find cross‐sectional and longitudinal changes in PET markers of synaptic vesicle protein 2A, sigma 1 receptor, and mitochondrial complex 1 in drug‐naive PD patients. Methods Twelve early drug‐naive PD patients and 16 healthy controls underwent a 3‐Tesla MRI and PET imaging to quantify volume of distribution of [11C]UCB‐J, [11C]SA‐4503, and [18F]BCPP‐EF for synaptic vesicle protein 2A, sigma 1 receptor, and mitochondrial complex 1, respectively. Nine PD patients completed approximately 1‐year follow‐up assessments. Results Reduced [11C]UCB‐J volume of distribution in the caudate, putamen, thalamus, brain stem, and dorsal raphe and across cortical regions was observed in drug‐naive PD patients compared with healthy controls. [11C]UCB‐J volume of distribution was reduced in the locus coeruleus and substantia nigra but did not reach statistical significance. No significant differences were found in [11C]SA‐4503 and [18F]BCPP‐EF volume of distribution in PD compared with healthy controls. Lower brain stem [11C]UCB‐J volume of distribution correlated with Movement Disorder Society Unified Parkinson's Disease Rating Scale part III and total scores. No significant longitudinal changes were identified in PD patients at follow‐up compared with baseline. Conclusions Our findings represent the first in vivo evidence of mitochondrial, endoplasmic reticulum, and synaptic dysfunction in drug‐naive PD patients. Synaptic dysfunction likely occurs early in disease pathophysiology and has relevance to symptomatology. Mitochondrial complex 1 and sigma 1 receptor pathology warrants further investigations in PD. Studies in larger cohorts with longer follow‐up will determine the validity of these PET markers to track disease progression.


  • Molecular Imaging of the Dopaminergic System in Idiopathic Parkinson's Disease

    by Edoardo R. de Natale, Flavia Niccolini, Heather Wilson, Marios Politis